Originally published by our sister publication General Surgery News
Ann Rogers, MD
In the past year, coinciding with the rising popularity of glucagon-like peptide-1 agents for treating obesity, many metabolic bariatric surgery programs across the country have seen surgical volume decline by 20% to 25%, with some smaller programs even closing their doors as a result. Although it can’t definitively be said that these steep declines are caused by GLP-1 agents, the conclusion